Potencial terapéutico de Curcuma longa y su principal componente activo, curcumina PLANTAS MEDICINALES 144 Bibliografía Aggarwal BB, Yuan W, Li S, Gupta SC. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. Mol Nutr Food Res. 2013; 57(9): 1529-42. Akaberi M, Sahebkar A, Emami SA. Turmeric and Curcumin: From Traditional to Modern Medicine. Adv Exp Med Biol. 2021; 1291: 15-39. An S, Jang E, Lee JH. Preclinical Evidence of Curcuma longa and Its Noncurcuminoid Constituents against Hepatobiliary Diseases: A Review. Evid Based Complement Alternat Med. 2020; 2020: 8761435. Ayati Z, Ramezani M, Amiri MS, Moghadam AT, Rahimi H, Abdollahzade A et al. Ethnobotany, Phytochemistry and Traditional Uses of Curcuma spp. and Pharmacological Profile of Two Important Species (C. longa and C. zedoaria): A Review. Curr Pharm Des. 2019; 25(8): 871-935. Bahrami A, Montecucco F, Carbone F, Sahebkar A. Effects of Curcumin on Aging: Molecular Mechanisms and Experimental Evidence. Biomed Res Int. 2021; 2021: 8972074. Berry A, Collacchi B, Masella R, Varì R, Cirulli F. Curcuma Longa, the “Golden Spice” to Counteract Neuroinflammaging and Cognitive Decline-What Have We Learned and What Needs to Be Done. Nutrients. 2021; 13(5): 1519. Chainoglou E, Hadjipavlou-Litina D. Curcumin in Health and Diseases: Alzheimer’s Disease and Curcumin Analogues, Derivatives, and Hybrids. Int J Mol Sci. 2020; 21(6): 1975. Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 2002; 512(1-3): 334-40. Gao TH, Liao W, Lin LT, Zhu ZP, Lu MG, Fu CM et al.. Curcumae rhizoma and its major constituents against hepatobiliary disease: Pharmacotherapeutic properties and potential clinical applications. Phytomedicine. 2022; 102: 154090. Gopinath H, Karthikeyan K. Turmeric: A condiment, cosmetic and cure. Indian J Dermatol Venereol Leprol. 2018; 84(1): 16-21. Jabczyk M, Nowak J, Hudzik B, Zubelewicz-Szkodzińska B. Curcumin in Metabolic Health and Disease. Nutrients. 2021; 13(12): 4440. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009; 14(2): 141-53. Erratum in: Altern Med Rev. 2009; 14(3): 277. Karlowicz-Bodalska K, Han S, Freier J, Smolenski M, Bodalska A. Curcuma longa as medicinal herb in the treatment of diabet- ic complications. Acta Pol Pharm. 2017; 74(2): 605-10. Kim Y, Clifton P. Curcumin, Cardiometabolic Health and Dementia. Int J Environ Res Public Health. 2018; 15(10): 2093. Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017; 57(13): 2889-95. Kotha RR, Luthria DL. Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects. Molecules. 2019; 24(16): 2930. Fuloria S, Mehta J, Chandel A, Sekar M, Rani NNIM, Begum MY et al. A Comprehensive Review on the Therapeutic Potential of Curcuma longa Linn. in Relation to its Major Active Constituent Curcumin. Front Pharmacol. 2022; 13: 820806. Li H, Sureda A, Devkota HP, Pittalà V, Barreca D, Silva AS et al. Curcumin, the golden spice in treating cardiovascular diseases. Biotechnol Adv. 2020; 38: 107343. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. J Med Chem. 2017; 60(5): 1620-37. Nocito MC, De Luca A, Prestia F, Avena P, La Padula D, Zavaglia L et al. Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability. Biomedicines. 2021; 9(10): 1476. Pivari F, Mingione A, Brasacchio C, Soldati L. Curcumin and Type 2 Diabetes Mellitus: Prevention and Treatment. Nutrients. 2019; 11(8): 1837. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, Ramirez-Tortosa M. Curcumin and Health. Molecules. 2016; 21(3): 264. Razavi BM, Ghasemzadeh Rahbardar M, Hosseinzadeh H. A review of therapeutic potentials of turmeric (Curcuma longa) and its active constituent, curcumin, on inflammatory disorders, pain, and their related patents. Phytother Res. 2021; 35(12): 6489-513. Soleimani V, Sahebkar A, Hosseinzadeh H. Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review. Phytother Res. 2018; 32(6): 985-95. Sultana S, Munir N, Mahmood Z, Riaz M, Akram M, Rebezov M et al. Molecular targets for the management of cancer using Curcuma longa Linn. phytoconstituents: A Review. Biomed Pharmacother. 2021; 135: 111078. Tasneem S, Liu B, Li B, Choudhary MI, Wang W. Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents. Pharmacol Res. 2019; 139: 126-40. Vafaeipour Z, Razavi BM, Hosseinzadeh H. Effects of turmeric (Curcuma longa) and its constituent (curcumin) on the metabolic syndrome: An updated review. J Integr Med. 2022; 20(3): 193-203. Villegas C, Perez R, Sterner O, González-Chavarría I, Paz C. Curcuma as an adjuvant in colorectal cancer treatment. Life Sci. 2021; 286: 120043. Zia A, Farkhondeh T, Pourbagher-Shahri AM, Samarghandian S. The role of curcumin in aging and senescence: Molecular mechanisms. Biomed Pharmacother. 2021; 134: 111119. se han desarrollado nuevos métodos para aumentar su biodisponibilidad, entre otros, el uso de curcumina liposomal, nanopartículas de curcumina y complejos de fosfolípidos. Por otro lado, se han obtenido derivados naturales y análogos sintéticos (a través de modificaciones químicas como grupos hidroxilo fenólicos, acilación, alquilación, glicosilación y aminoacilación) con los que se ha logrado una mayor biodisponibilidad y merecen ser investigados en estudios clínicos de adecuado diseño. Figura 4. Representación esquemática del potencial terapéutico de la cúrcuma y la curcumina por su efecto sobre diferentes dianas biológicas. DM2: diabetes mellitus tipo 2.
RkJQdWJsaXNoZXIy MTEwMTU=